Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label randomized trial of SHR-A1921 vs investigator's choice chemotherapy in platinum-resistant recurrent epithelial ovarian cancer
CTR20241535Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tizetatug rezetecan in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started May 2024; status: active.
02
Drugs
tizetatug rezetecan
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20241535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241535.